Abstract：Objective To compare the clinical efficacy between simultaneous integrated boost (SIB) and sequential boost (SB) using intensity-modulated radiotherapy (IMRT),and investigate the long-term clinical efficacy and adverse events of SIB-IMRT in combination with chemotherapy in the treatment of esophageal cancer. Methods Clinical data of 330 patients diagnosed with esophageal cancer undergoing radical chemoradiotherapy in Fourth Hospital of Hebei University from January 2006 to December 2015 were respectively analyzed. All patients were assigned into the SIB-IMRT (n=135) and SB-IMRT groups (n=195).All patients received definitive radiotherapy with elective nodal irradiation (ENI).After the propensity score matching (PSM),105 patients were enrolled in each group. Kaplan-Meier method was used to survival analysis. Cox model was used to multivariate prognostic analysis. Results Prior to PSM,the 1-,3-and 5-year local control rates were 80.1%,58.3%,46.7% and 72.1%,44.9%,40.5% in the SIB-IMRT and SB-IMRT groups (P=0.050),and the 1-,3-and 5-year OS rates were 81.4%,51.9%,43.5% and 80.5%,37.9%,22.3%(P=0.014),respectively. After the PSM,the 1-,3-and 5-year LC rates were 80.2%,54.2%,43.9% and 75.5%,47.2%,41.2%(P=0.264),and the 1-,3-and 5-year OS rates were 78.9%,49.0%,40.8% and 83.3%,41.7%,24.8%(P=0.265),respectively. Multivariate analysis demonstrated that TNM staging was an independent prognostic factor in the SIB-IMRT group,whereas TNM staging and chemotherapy served as the independent prognostic factors in the SB-IMRT group. Stratified analysis revealed that the LC rate in the SIB-IMRT was significantly higher than that in the SB-IMRT group when radiotherapy alone was performed (P=0.018).The OS rate in the SIB-IMRT group was equally higher compared with that in the SB-IMRT group. Conclusions The LC and OS rates are almost identical after SB-IMRT and SIB-IMRT in the treatment of esophageal cancer,whereas the prognostic survival in the SIB-IMRT group is significantly longer compared with that in the SB-IMRT group during radiotherapy alone. The findings remain to be validated by multi-center investigations with a large sample size.
Deng Wenzhao,Mamady Keita,Li Shuguang et al. Comparative study between simultaneous integrated and sequential boost using intensity-modulated radiotherapy for esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(10): 900-905.
[1] Cox JD,StetzJ,Paiak TF.Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the Europ-OrganiT-onfor Research and Treatment of Cancer (EORTC)[J].Int J Radial On eol Biol Phys,1995,31(5):1341-1346. [2] 祝淑钗,么伟楠,李娟,等.食管癌非手术治疗临床分期新标准的对比研究[J].中华放射肿瘤学杂志,2016,25(2):109-113.DOI:10.3760/ cma.j.issn.1004-4221.2016.02.005. Zhu SC,Mo WN,Li J,et al. A comparative study of new clinical staging standards for non-surgical treatment of esophageal cancer[J].Chin J Radiat Oncol,2016,25(2):109-113.DOI:10.3760/cma.j.issn.1004-4221.2016.02.005. [3] 殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].第4版.北京:中国协和医科大学出版社,2008:546-577. Yin WB,Yu ZH,Xu GZ,et al. Tumor radiotherapy[M].4 ed. Beijing:China Union Medical University Press,2008:546-577. [4] Alongi F,Fogliata A,Navarria P,et al. Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer[J].Strahlenther Onkol,2012,188(11):990-996.DOI:10.1007/s00066-012-0171-7. [5] Peponi E,Glanzmann C,Kunz G,et al. Simultaneous integrated boost intensity-modulated radiotherapy in nasopharyngeal cancer[J].Strahlenther Onkol,2010,186(3):135-142.DOI:10.1007/s00066-010-2048-y. [6] Kim K,Wu HG,Kim HJ,et al. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma[J].Head Neck J Sci Spec,2009,31(9):1121-1128.DOI:10.1002/hed.21076. [7] Welsh J,Seyedin S,Allen P,et al. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer[J].J Thora Oncol,2016,12(2):375-382.DOI:10.1016/j.jtho.2016.10.013. [8] 祝淑钗,董辉,刘志坤,等.早期食管癌根治性放射治疗不同照射范围的比较研究[J].中华放射肿瘤学杂志,2015,24(6):615-618.DOI:10.3760/ cma.j.issn.1004-4221.2015.06.005. Zhu SC,Dong H,Liu ZK,et al. Comparative study on different irradiation ranges of early radical radiotherapy for esophageal carcinoma[J].Chin J Radiat Oncol,2015,24(6):615-618.DOI:10.3760/cma.j.issn.1004-4221.2015.06.005. [9] 董辉,祝淑钗,苏景伟,等.食管癌根治性放疗中ENI与IFI失败模式研究[J].中华放射肿瘤学杂志,2014,23(6):479-484.DOI:10.3760/ cma.j.issn.1004-4221.2014.06.005. Dong H,Zhu SC,Su JW,et al. Failure pattern of ENI and IFI in radical radiotherapy for esophageal carcinoma[J].Chin J Radiat Oncol,2014,23(6):479-484.DOI:10.3760/cma.j.issn.1004-4221.2014.06.005. [10] Yu WW,Zhu ZF,Fu XL,et al. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma-Early results of a phase Ⅱ study[J].Strahlenther Onkol,2014,190(11):979-986.DOI:10.1007/s00066-014-0636-y. [11] Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG85-01)[J].JAMA,1999,281(17):1623-1627.DOI:10.1001/jama.281.17.1623. [12] Minsky BD,Pajak TF,Ginsberg RJ,et al. INT 0123(radiation therapy oncology group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standarddose radiation therapy[J].J Clin Oncol,2002,20(5):1167-1174.DOI:10.1200/JCO.2002.20.5.1167. [13] Chen JZ,Guo H,Zhai TT,et al. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer:a phase Ⅱstudy[J].Oncotarget,2016,7(16):22711-22719.DOI:10.18632/oncotarget.8050.
2018, Vol. 27 
